AvalehtNCYT • LON
add
Novacyt SA
Viimane sulgemishind
51,00 GBX
Tänane vahemik
48,50 GBX - 50,00 GBX
Aasta vahemik
39,07 GBX - 86,00 GBX
Turuväärtus
40,37 mln EUR
Keskmine maht
227,42 tuh
P/E suhe
-
Dividendimäär
-
Põhibörs
EPA
Uudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
| (GBP) | dets 2023info | Y/Y muutus |
|---|---|---|
Käive | 4,12 mln | 81,82% |
Põhitegevusega seonduv kulu | 12,52 mln | 48,31% |
Puhastulu | −9,97 mln | −17,10% |
Puhaskasumimarginaal | −242,04 | 35,59% |
Puhaskasum aktsia kohta | — | — |
EBITDA | −7,10 mln | −41,10% |
Tõhus maksumäär | 2,93% | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
| (GBP) | dets 2023info | Y/Y muutus |
|---|---|---|
Sularaha ja lühiajalised investeeringud | 44,06 mln | −49,34% |
Kogu vara | 133,82 mln | −5,03% |
Kõik kohustused | 46,57 mln | 81,32% |
Kogu omakapital | 87,24 mln | — |
Emiteeritud aktsiate arv | 70,63 mln | — |
Hinna ja väärtuse suhe P/B | 0,41 | — |
Varade tasuvus | −21,46% | — |
Kapitali tasuvus | −28,44% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
| (GBP) | dets 2023info | Y/Y muutus |
|---|---|---|
Puhastulu | −9,97 mln | −17,10% |
Põhitegevuse rahakäive | −9,65 mln | −59,94% |
Investeeringute raha | −7,47 mln | −3 853,70% |
Finantseerimise raha | −1,72 mln | −1 360,85% |
Raha ja raha ekvivalentide muutus | −18,84 mln | −197,44% |
Tasuta rahavoog | −3,81 mln | −56,02% |
Teave
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying an extensive range assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Tegevjuht
Asutatud
2006
Veebisait
Töötajate arv
237
